ClinicalTrials.gg
Active, not recruitingNCT05269680STAR-LIFEUpdated Jun 16, 2026

STAR-LIFE: a Post-market Registry on MINIject

An observational study in Open Angle Glaucoma, sponsored by iSTAR Medical. Active, not recruiting at 15 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by iSTAR Medical · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
320
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Glaucoma, Open-Angle by iSTAR Medical — 1 open to participants now, 5 under way, none of them phase 3. Glaucoma, Open-Angle · iSTAR Medical.

Started
2022
the only one that year
Observational
3 of 10
none open now
Registered
9th of 10
by date

Among the 10 studies in Glaucoma, Open-Angle by iSTAR Medical, this one is the only one that started in 2022, is one of 3 observational ones, and was the 9th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

1 of the 10 studies in Glaucoma, Open-Angle by iSTAR Medical is open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Glaucoma, Open-Angle by iSTAR Medical, or all of them as a file.
02

Study summary

As part of the post-market clinical follow-up (PMCF), this registry is developed to ensure real-world data collection on MINIject device.

Read the detailed description

The goal of the registry is to collect data of the MINIject in a real-life setting. The registry has 3 main objectives: the collection of real-world evidence on the usability of the device, the patient reported outcomes, and the device safety over a period of 2 years after surgery.

03

Conditions studied

  • Open Angle Glaucoma

Browse trials for

Keywords

  • Open Angle Glaucoma
  • Minimally Invasive Glaucoma Surgery
  • MINIject
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patient diagnosed with open angle glaucoma

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18+ years
  • diagnosed with open angle glaucoma, who has been or will be implanted with CE-marked MINIject
  • able to give consent

Exclusion criteria

Exclusion Criteria:

  • eyes with angle closure glaucoma
  • eyes with traumatic, malignant, uveitic or neovascular glaucoma or discernible congenital anomalies of the anterior chamber angle
  • patients with known intolerance or to silicone
  • patients unable to give consent
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
320 participants (estimated)
Patient registry
No

Interventions

  • DeviceImplant Miniject

    each participant receives an implant Miniject and are followed during 2 years

06

What researchers measure

Primary outcomes

  1. Unexpected incidents and/or serious reportable incidents

    Collection of incidents (nature (ocular or non-ocular), number and severity) throughout the study. The number of unexpected incidents and the number of individuals presenting at least one event will be reported.

    Time frame: From enrollment up to 2 years after surgery (study completion)

Secondary outcomes

  1. Surgeon assessment of Device Usability

    The Device usability will be assessed by the surgeon using a study-specific usability questionnaire evaluating device preparation, handling, and use during surgery. Questionnaire items may include categorical ratings, ordinal scales, and free-text comments, as applicable.

    Time frame: The surgery day

  2. Eye-related Quality of Life Assessed Using the SHPC-18 questionnaire

    Quality of life will be assessed using the Symptom and Health Problem Checklist (SHPC-18) questionnaire, an 18 item instrument for patients treated for glaucoma. The questionnaire includes two domains: local eye symptoms (7 items) and Visual function problems (11 items). Each item is scored and a total "bothersome score" is calculated by summing all 18 items (range 0-1800) and dividing by 18, resulting in a final score ranging from 0 to 100. Higher scores indicate greater symptom burden and worse quality of life. Change from baseline will be evaluated at 12 and 24 months.

    Time frame: Baseline, 12 and 24 months

  3. IOP measurement

    IOP measurements at each follow-up visit over time and changes compared to baseline

    Time frame: Baseline, 1 day and 1, 3, 6, 12 and 24 months

  4. Ocular medication use

    Ocular medication use at each follow-up visit and changes compared to baseline

    Time frame: From enrollment through 2 years after surgery

  5. Investigator Assessment of Ocular Symptoms Using a 6-Category Severity Scale

    At each follow-up visit, the investigator will assess the presence and severity of ocular symptoms (including blurred vision, glare, halos, dryness, foreign body sensation, and other reported symptoms) using the categories: absent, mild, moderate, severe, very severe, or unknown. Changes from baseline will be evaluated.

    Time frame: From enrollment until 2 years post-surgery

  6. BCVA testing

    Best Corrected Visual Acuity (BCVA) outcomes at each follow-up visit and changes compared to baseline

    Time frame: Baseline, 1, 3, 6, 12, 24 months

  7. Visual field

    Visual field outcomes at each follow-up visit and changes compared to baseline

    Time frame: Baseline, 6, 12 and 24 months

  8. Additional ocular surgery post-implantation

    Additional ocular surgery post-implantation will be registered through the study

    Time frame: From surgery until 2 years post-surgery

07

Study locations

15 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Dec 2028, 77 months after the start.

Of 53 observational studies under Glaucoma, Open-Angle, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12. This study's planned 77 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2022
First posted
Mar 8, 2022
StartActual
Jul 20, 2022
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05269680
Lead sponsor
iSTAR Medical
Responsible party
Sponsor
First posted
Mar 8, 2022
Start date
Jul 20, 2022
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Jun 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion